, ,

Ovarian Cancers

Advances through International Research Cooperation (GINECO, ENGOT, GCIG)

Specificaties
Gebonden, blz. | Engels
Springer International Publishing | e druk, 2016
ISBN13: 9783319321080
Rubricering
Juridisch :
Springer International Publishing e druk, 2016 9783319321080
€ 147,39
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Samenvatting

This book provides an overview of the latest
developments in the concepts and management of ovarian cancer. The new data
presented throughout opens the way to radically different therapeutic
approaches. Surgery remains the core of ovarian cancer treatment, but its
ultimate goal and the standard surgical procedure have evolved, giving rise to
the question of how to label expert centers for debulking surgery. Neo-adjuvant
chemotherapy is becoming more popular and is also a new field for testing novel
drug combinations.

Over recent years, ovarian cancer management
has embraced molecular biology. It is now more correct to talk about cancers of
the ovary rather than ovarian cancer, since it is not a unique disease but
several entities with different molecular drivers. The significant advances in
drugs targeting the microenvironment or the tumor cell DNA repair mechanisms
are presented in detail together with exciting future perspectives.

All these advances would not have been possible
without collaborative groups such as the GINECO group in France and their
integration in wider clinical research networks at the European (ENGOT) and
international (GCIG) level.

Specificaties

ISBN13:9783319321080
Taal:Engels
Bindwijze:gebonden
Uitgever:Springer International Publishing

Inhoudsopgave

Ovarian cancer management.- Clinical research in Europe dedicated to ovarian cancers.- Oncogenetics.- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality.- How to evaluate tumor burden before therapeutic decision.- Value of lymphadenectomy.- HYPEC: what is the evidence?.- Onco-fertility applied to ovarian cancers.- First-line systemic therapy (chemo/antiangiogenics).- Elderly.- Treatment at relapse (surgery & systemic treatments).- How to evaluate QoL.- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers.- Particular types of ovarian cancers.- High grade serous carcinoma & BRCA mutation anti-PARP.- Borderline and low grade carcinoma.- Clear Cell carcinoma.- Endometrioid carcinoma.- Mucinous carcinoma.- Carcinosarcoma.- Germ cell tumors.- Sex cord tumors.- Very rare ovarian malignant tumors including small cell carcinoma.

Ovarian cancer management.- Clinical research in Europededicated to ovarian cancers.-
Oncogenetics.- Debulking surgery: Interval debulking surgery vs primary: pro and con. How to evaluate quality.- How to evaluate tumor burden before therapeutic decision.- Value of lymphadenectomy.- HYPEC: what is the evidence?.- Onco-fertility applied to ovarian cancers.- First-line systemic therapy (chemo/antiangiogenics).- Elderly.- Treatment at relapse (surgery  & systemic  treatments).- How to evaluate QoL.- The future in ovarian cancers & place of the new immunotherapies in ovarian cancers.- Particular types of ovarian cancers.- High  grade  serous  carcinoma & BRCA mutation anti-PARP.- Borderline and low grade carcinoma.- Clear Cell carcinoma.- Endometrioid carcinoma.- Mucinous  carcinoma.- Carcinosarcoma.- Germ cell tumors.- Sex cord tumors.- Very rare ovarian malignant tumors including small cell carcinoma.

Net verschenen

€ 147,39
Levertijd ongeveer 9 werkdagen
Gratis verzonden

Rubrieken

    Personen

      Trefwoorden

        Ovarian Cancers